Germline Warfare
By Ralph Brave,
The Nation
| 04. 07. 2003
A most remarkable event occurred in the weeks preceding the
June 2000 announcement of the completion of the first draft
of the human genome DNA code: One of the leaders of the genome
project publicly called for strict limits on what the scientific
community should be permitted to do with the human genetic blueprint
now in hand.
At a conference at MIT, Dr. Eric Lander, leader of the team
that decoded the largest portion of the genome, called the conference
to attention with this surprisingly stark suggestion:
Already, there are well-meaning discussions about improving
the human DNA. I find this somewhat hubristic myself. [The human
genome] has been 3.5 billion years in the making. We've been
able to read it for the last, oh, I don't know, year or so.
And we suddenly think we could write the story better? It's
very amusing.
There is the prospect that by changing things we might put
off aging, prevent cancer, improve memory. I find it a very
difficult question. For my own part, I would put an absolute
ban in place on...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...